IS7138A - Alkýn-arýl fosfódíesterasa-4 hindrar - Google Patents

Alkýn-arýl fosfódíesterasa-4 hindrar

Info

Publication number
IS7138A
IS7138A IS7138A IS7138A IS7138A IS 7138 A IS7138 A IS 7138A IS 7138 A IS7138 A IS 7138A IS 7138 A IS7138 A IS 7138A IS 7138 A IS7138 A IS 7138A
Authority
IS
Iceland
Prior art keywords
alkyn
inhibitors
phosphodiesterase
aryl
aryl phosphodiesterase
Prior art date
Application number
IS7138A
Other languages
English (en)
Inventor
Guay Daniel
Girard Mario
Hamel Pierre
Laliberte Sebastian
Friesen Richard
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Publication of IS7138A publication Critical patent/IS7138A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
IS7138A 2001-08-29 2004-01-30 Alkýn-arýl fosfódíesterasa-4 hindrar IS7138A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31609301P 2001-08-29 2001-08-29
PCT/CA2002/001324 WO2003018579A1 (en) 2001-08-29 2002-08-27 Alkyne-aryl phosphodiesterase-4 inhibitors

Publications (1)

Publication Number Publication Date
IS7138A true IS7138A (is) 2004-01-30

Family

ID=23227432

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7138A IS7138A (is) 2001-08-29 2004-01-30 Alkýn-arýl fosfódíesterasa-4 hindrar

Country Status (28)

Country Link
US (2) US6743802B2 (is)
EP (2) EP2305677A1 (is)
JP (1) JP4157035B2 (is)
KR (1) KR100928849B1 (is)
CN (1) CN100338061C (is)
AR (1) AR036365A1 (is)
AU (1) AU2002322940B2 (is)
BR (1) BR0212042A (is)
CA (1) CA2456817C (is)
DO (1) DOP2002000456A (is)
EA (1) EA006800B1 (is)
EC (1) ECSP044992A (is)
GE (1) GEP20063805B (is)
HK (1) HK1080073B (is)
HR (1) HRP20040151A2 (is)
HU (1) HUP0401729A3 (is)
IL (1) IL160213A0 (is)
IS (1) IS7138A (is)
JO (1) JO2311B1 (is)
MX (1) MXPA04001889A (is)
NO (1) NO330521B1 (is)
NZ (1) NZ530931A (is)
PE (1) PE20030416A1 (is)
PL (1) PL367716A1 (is)
RS (1) RS17004A (is)
UA (1) UA75957C2 (is)
WO (1) WO2003018579A1 (is)
ZA (1) ZA200400952B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
AU2003291418A1 (en) * 2002-11-15 2004-06-15 Merck And Co., Inc. Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
AR042194A1 (es) * 2002-11-22 2005-06-15 Merck & Co Inc Metodo para preparar inhibidores de fosfodiesterasa - 4
US20060040981A1 (en) * 2002-11-22 2006-02-23 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20080119509A1 (en) * 2004-04-26 2008-05-22 Sophie-Dorothee Clas Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
JP4264388B2 (ja) * 2004-07-01 2009-05-13 富士通株式会社 半導体チップの接合方法および接合装置
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7687490B2 (en) * 2005-04-12 2010-03-30 Meiji Seika Kaisha, Ltd. 2-thioethenyl substituted carbapenem derivatives
JP2006016407A (ja) * 2005-06-15 2006-01-19 Yamaha Motor Co Ltd ホスホジエステラーゼ阻害剤
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007036029A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007070319A2 (en) * 2005-12-13 2007-06-21 Wyeth Dibenzonaphthyridine derivatives and methods of use thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP2546232A1 (en) 2007-06-20 2013-01-16 Merck Sharp & Dohme Corp. Diphenyl Substituted Alkanes
RU2470639C2 (ru) * 2007-10-25 2012-12-27 Мерк Фросст Кэнада Лтд. Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2533780B1 (en) 2010-02-12 2017-08-23 AskAt Inc. 5-ht4 receptor agonists for the treatment of dementia
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103214478B (zh) * 2012-01-19 2015-07-15 山东轩竹医药科技有限公司 吡啶并氧代哒嗪衍生物
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
MX2021007938A (es) 2018-12-28 2022-01-24 Regeneron Pharma Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
EP0577024B1 (de) 1992-07-01 1996-10-16 Hoechst Aktiengesellschaft 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
EP0738268B1 (en) 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0765867A1 (de) 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19622370A1 (de) 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
IL130124A0 (en) 1996-12-11 2000-06-01 Basf Ag Ketobenzamides as calpain inhibitors
EP0958297A1 (en) * 1997-08-06 1999-11-24 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
AU8780898A (en) 1997-08-20 1999-03-08 First Data Corporation Interactive tax payment system
KR20010005830A (ko) * 1998-01-29 2001-01-15 도리이 신이치로 타입 ⅳ 포스포디에스테라제 억제활성을 지닌 1-사이클로알킬-1,8-나프틸리딘-4-온 유도체
AP2001002068A0 (en) * 1998-08-11 2001-03-31 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors.
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Also Published As

Publication number Publication date
CN1639161A (zh) 2005-07-13
NO330521B1 (no) 2011-05-09
UA75957C2 (en) 2006-06-15
KR20040034672A (ko) 2004-04-28
MXPA04001889A (es) 2004-06-15
JP2005508313A (ja) 2005-03-31
EP1436290B8 (en) 2013-12-04
HRP20040151A2 (en) 2006-05-31
RS17004A (sr) 2007-02-05
JO2311B1 (en) 2005-09-12
EP1436290A1 (en) 2004-07-14
JP4157035B2 (ja) 2008-09-24
HUP0401729A3 (en) 2012-09-28
HK1080073A1 (zh) 2006-04-21
IL160213A0 (en) 2004-07-25
US6743802B2 (en) 2004-06-01
WO2003018579A1 (en) 2003-03-06
ZA200400952B (en) 2004-10-22
EA200400361A1 (ru) 2004-08-26
DOP2002000456A (es) 2003-02-28
EP2305677A1 (en) 2011-04-06
ECSP044992A (es) 2004-04-28
NO20041293D0 (no) 2004-03-26
CA2456817A1 (en) 2003-03-06
CA2456817C (en) 2010-11-30
NZ530931A (en) 2005-12-23
US20050070569A1 (en) 2005-03-31
PL367716A1 (en) 2005-03-07
EA006800B1 (ru) 2006-04-28
US20030114478A1 (en) 2003-06-19
PE20030416A1 (es) 2003-05-15
HUP0401729A2 (hu) 2004-12-28
EP1436290B1 (en) 2013-09-18
CN100338061C (zh) 2007-09-19
AR036365A1 (es) 2004-09-01
HK1080073B (zh) 2008-08-08
KR100928849B1 (ko) 2009-11-30
NO20041293L (no) 2004-05-27
AU2002322940B2 (en) 2007-03-01
BR0212042A (pt) 2004-08-17
GEP20063805B (en) 2006-04-25

Similar Documents

Publication Publication Date Title
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DE60234125D1 (de) E inhibitoren
PT1370553E (pt) Inibidores de rhoquinase
DE60218138D1 (de) Rho-kinase inhibitoren
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
NO20042121D0 (no) Kinolinforbindelse
DE60320933D1 (de) Rho-kinase inhibitoren
NO20034042D0 (no) Metallproteinase-inhibitorer
NO20034308D0 (no) Nye tyrokinase-inhibitorer
ATE402148T1 (de) Substituierte pyridinylamine
NO20034032L (no) Metallproteinase-inhibitorer
DE50206892D1 (de) Substituierte imidazotriazinone
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20023013D0 (no) Substituerte 8-arylkinolinfosfodiesterase-4-inhibitorer
NO20014597D0 (no) Fremgangsmåte
NO20032807D0 (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE60311233D1 (de) Chinolinderivate
DE60229669D1 (de) X-2 inhibitoren
DE60204723D1 (de) Plattenspieler
DE60216967D1 (de) Substituierte cyclohexanderivate
DE60219659D1 (de) Heterocyclische retioidverbindungen
SE0102987D0 (sv) Länsa